RxDoctor Payments DataLook up a doctor →

Robert Martindale, MD

Surgery · Portland, ORNPI 1154339604

Payments from drug & device makers

$801,031in general payments, 2019–2025

Across 603 payments — averaging $1328.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$506K
  • Fresenius Kabi USA, LLC$166K
  • Nestle Healthcare Nutrition Inc.$59K
  • Baxter Healthcare$42K
  • Medtronic$20K
  • Davol Inc.$6K
  • plus $2K from 5 others
$60in research payments, 2019–2025

Across 1 payment — averaging $59.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • AbbVie$60

What the payments were for

  • Consulting fees$254,85032%
  • Speaking & faculty fees$449,81857%
  • Travel & lodging$76,32610%
  • Food & beverage$14,3142%
  • Education$1440%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$801,031 in reported general payments places this provider in the 95th percentile of 386 surgery providers in Oregon.

See all surgery providers in Oregon

Medicare billing

Part B allowed, 2024
$50,793
Medicare patients
70
Services billed
232

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase17$37,669
ClinisolParenteral Amino Acid 15% No.536$6,570
Promethazine Hcl62$3,399
Lactated RingersRinger's Solution,lactated80$2,968
LoperamideLoperamide Hcl33$1,518
Sodium Chloride0.9 % Sodium Chloride16$346
Oxycodone Hcl12$199
Magnesium Sulfate11$163
Ondansetron HclOndansetron Hcl/Pf11$41

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon$505,535$37,66917 claims
Fresenius Kabi USA, LLCSodium Chloride, Magnesium Sulfate$166,491$50927 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 386 surgery providers in Oregon.

Other surgery in Portland

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →